Deng Xianding, Garcia-Knight Miguel A, Khalid Mir M, Servellita Venice, Wang Candace, Morris Mary Kate, Sotomayor-González Alicia, Glasner Dustin R, Reyes Kevin R, Gliwa Amelia S, Reddy Nikitha P, Sanchez San Martin Claudia, Federman Scot, Cheng Jing, Balcerek Joanna, Taylor Jordan, Streithorst Jessica A, Miller Steve, Sreekumar Bharath, Chen Pei-Yi, Schulze-Gahmen Ursula, Taha Taha Y, Hayashi Jennifer M, Simoneau Camille R, Kumar G Renuka, McMahon Sarah, Lidsky Peter V, Xiao Yinghong, Hemarajata Peera, Green Nicole M, Espinosa Alex, Kath Chantha, Haw Monica, Bell John, Hacker Jill K, Hanson Carl, Wadford Debra A, Anaya Carlos, Ferguson Donna, Frankino Phillip A, Shivram Haridha, Lareau Liana F, Wyman Stacia K, Ott Melanie, Andino Raul, Chiu Charles Y
Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 94158, USA.
Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Cell. 2021 Jun 24;184(13):3426-3437.e8. doi: 10.1016/j.cell.2021.04.025. Epub 2021 Apr 20.
We identified an emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the western United States. Named B.1.427/B.1.429 to denote its two lineages, the variant emerged in May 2020 and increased from 0% to >50% of sequenced cases from September 2020 to January 2021, showing 18.6%-24% increased transmissibility relative to wild-type circulating strains. The variant carries three mutations in the spike protein, including an L452R substitution. We found 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation common to variants B.1.1.7, B.1.351, and P.1. Antibody neutralization assays revealed 4.0- to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively. The increased prevalence of a more transmissible variant in California exhibiting decreased antibody neutralization warrants further investigation.
Science. 2021-8-6
Eur Rev Med Pharmacol Sci. 2021-9
J Biomed Sci. 2021-11-23
Transbound Emerg Dis. 2023-5-9
N Engl J Med. 2021-4-15
N Engl J Med. 2021-4-15
Zotero 插件
